Genesis Therapeutics, Inc. — Form D
Genesis Therapeutics, Inc. of BURLINGAME, CA, a company, filed a Form D exempt-offering notice with the SEC on 2023-08-25. The offering totals $224.0M, of which $224.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-08-25
- Form: D
- Accession: 0001775819-23-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $224.0M
- Amount sold: $224.0M
- Investors: 50
- Date of first sale: 2023-08-10
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-490705
Issuer
- Name: Genesis Therapeutics, Inc.
- CIK: 0001775819
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 1440 CHAPIN AVE, BURLINGAME, CA, 94010
- Phone: 203-615-4567
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| LEONARD BELL | Director | BURLINGAME, CA |
| EVAN FEINBERG | Director | BURLINGAME, CA |
| Kris Jenner | Director | Baltimore, MD |
| Vijay Pande | Director | Richmond, CA |
| PEPTIBOON PRASIT | Director | BURLINGAME, CA |
| EVAN FEINBERG | Executive Officer | BURLINGAME, CA |
| WILLIAM MCCARTHY | Executive Officer | BURLINGAME, CA |
| PEPTIBOON PRASIT | Executive Officer | BURLINGAME, CA |
| BENJAMIN SKLAROFF | Executive Officer | BURLINGAME, CA |
| Stephen Dann | Executive Officer | LONDON, X0 |
| NICHOLAS STOCK | Executive Officer | BURLINGAME, CA |
Other filings by this issuer (2)
More